by sctpn-new | May 13, 2020 | Media Release, Research Trials
CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001™ for the Treatment of Severe Hemoglobinopathies – CTX001 has received Orphan Drug Designation from the U.S. Food and Drug...
by sctpn-new | Apr 18, 2020 | Advocacy & Education, POES Government 101 Education
The New York State Sickle Cell Disease Partnership (NYSSCDP) and the New York Coalition for Bleeding Disorders (NYCBD) were scheduled to be in Albany Monday, March 16, at the State Legislative Office Building (LOB). We planned tabling activities and meeting with...
by sctpn-new | Apr 17, 2020 | Uncategorized
Practicing Social Unity Since the 1990s, the primary focus of the Sickle Cell Thalassemia Patients Network (SCTPN) has been to advocate for the sickle cell community while raising awareness about the disease, because of the extreme need to fill the void for...
by sctpn-new | Sep 11, 2019 | Uncategorized
SCTPN Community Health Worker Sabrina J. Lewis Shares Her Story About Advocacy and Care Coordination in the SCD Community As a Community Health Worker with the Sickle Cell Thalassemia Patient Network, various experiences have opened my eyes to truths of what families...
by sctpn-new | Sep 6, 2019 | Uncategorized
In an effort to increase outreach in to the Latin community in northern Manhattan and the Bronx, the Sickle Cell Thalassemia Patients Network (SCTPN hosted its second English/Spanish Sickle Cell 101 Forum, at the Northern Manhattan I C. The forum is part...
